Medicine and Dentistry
ANCA Associated Vasculitis
80%
COVID-19
62%
Glomerulonephritis
53%
Diseases
39%
Urine Sampling
27%
Renal Replacement Therapy
25%
Telehealth
25%
Glucocorticoid
25%
Disease Activity
25%
Nephrology
25%
Neutrophil
25%
Raman Spectrometry
25%
Continuous Positive Airway Pressure
25%
Intensive Care
25%
Risk Stratification
25%
Patient-Reported Outcome
25%
Personal Experience
25%
Sparsentan
25%
Autoantibodies
25%
Immunoglobulin A Nephropathy
25%
Controlled Clinical Trial
25%
Interim Analysis
25%
Biopsy
23%
Irbesartan
18%
Immunosuppressive Treatment
17%
Glomerulus
16%
Biological Marker
16%
Nephrologist
12%
Infection
11%
Renal Biopsy
11%
Coronavirinae
10%
Spontaneous Remission
10%
Consultation
9%
Patient Experience
8%
Spectroscopy
8%
Health Care Cost
8%
Idiopathic Pulmonary Fibrosis
8%
Predictive Modeling
8%
Biopsy Sample
8%
Adverse Event
8%
Rituximab
8%
Proteinuria
6%
Pandemic
6%
Apoplexy
6%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
High Risk Population
5%
Prognostication
5%
Kaplan Meier Method
5%
Anticoagulation
5%
Mortality Rate
5%
Pharmacology, Toxicology and Pharmaceutical Science
ANCA Associated Vasculitis
100%
Disease
47%
Glucocorticoid
28%
Sparsentan
25%
Controlled Clinical Trial
25%
Immunoglobulin A Nephropathy
25%
Irbesartan
18%
Rituximab
11%
Disease Duration
8%
Symptom
8%
Adverse Event
8%
Proteinuria
6%
Infection
6%
Coronavirinae
5%
Cross-Sectional Study
5%
SARS Coronavirus
5%
